NeurovascularMedicine.com
MEDICAL DISCLAIMER:The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website.









Edoxaban


Learning objectives

  • Learning
  • Understand
  • Integrate
  • Reflect

Indicated in non rheumatic AF with one of the following previous stroke or transient ischaemic attack, CCF, age > 75 years, diabetes mellitus or hypertension

About : Always check the BNF link here
  • A DOAC
Mode of action
  • Direct and reversible inhibitor of activated factor Xa
Indications/Dose
  • DVT/PE: Edoxaban 60 mg OD following 5 days LMWH, Edoxaban 30 mg OD in those weight < 60 Kg
  • Non Rheumatic AF: Edoxaban 60 mg OD, Edoxaban 30 mg OD in those weight < 60 Kg
  • DVT/VTE prevention: not licensed.
Interactions
  • Ciclosporin, dronedarone, Erythromycin, or Ketoconazole: reduced dose to 30 mg
Cautions
  • Other Anticoagulants and antithrombotic drugs or coagulopathy
  • High HAS BLED score, Poorly controlled BP, Liver disease
Contraindications
  • Renal failure, Active pathological bleeding, Severe hypersensitivity reaction
  • Significant risk of major bleeding: GI ulcer, oesophageal varices
  • Recent brain, spine, or ophthalmic surgery
  • Recent intracranial haemorrhage, malignant neoplasms, vascular aneurysm
Side effects
  • Haemorrhage, Urticaria
References